Established disease-modifying treatments in relapsing-remitting multiple sclerosis

Jiwon Oh, Paul W. O'Connor

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


The purpose of this review is to summarize mechanisms of action, efficacy and safety of established disease-modifying treatments (DMTs) that have been widely approved for use in relapsing-remitting multiple sclerosis (RRMS). Recent findings Established and widely used DMTs for the treatment of RRMS include the interferon-β agents, glatiramer acetate, natalizumab, fingolimod, teriflunomide and dimethyl fumarate. These DMTs have quite different mechanisms of action, efficacy and safety and tolerability profiles, which are summarized concisely in the article below. Summary The treatment algorithm for RRMS is becoming increasingly complex with the ever-expanding armamentarium of DMTs. The choice of DMT will become an increasingly individual decision, based on a number of factors, including disease activity and severity, safety/tolerability profile and patient preference. Neurologists treating patients with multiple sclerosis (MS) will need a thorough knowledge of efficacy, safety and tolerability of the spectrum of DMTs available for treatment of RRMS to provide comprehensive clinical care.

Original languageEnglish (US)
Pages (from-to)220-229
Number of pages10
JournalCurrent opinion in neurology
Issue number3
StatePublished - Jun 6 2015
Externally publishedYes


  • Efficacy
  • established disease-modifying treatments
  • relapsing-remitting multiple sclerosis
  • safety and tolerability

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Established disease-modifying treatments in relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Cite this